ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $3,620,028 | $2,770,681 | $3,055,917 |
| - Cash | $257,996 | $253,637 | $217,696 | $319,589 |
| + Debt | $43,026 | $56,294 | $56,006 | $51,995 |
| Enterprise Value | – | $3,422,685 | $2,608,991 | $2,788,323 |
| Revenue | $278,633 | $264,566 | $244,317 | $259,602 |
| % Growth | 5.3% | 8.3% | -5.9% | – |
| Gross Profit | $256,986 | $243,832 | $223,925 | $237,799 |
| % Margin | 92.2% | 92.2% | 91.7% | 91.6% |
| EBITDA | $47,545 | $35,309 | $22,241 | $12,202 |
| % Margin | 17.1% | 13.3% | 9.1% | 4.7% |
| Net Income | $71,779 | $26,666 | $18,987 | $143,742 |
| % Margin | 25.8% | 10.1% | 7.8% | 55.4% |
| EPS Diluted | 0.42 | 0.16 | 0.11 | 0.86 |
| % Growth | 162.5% | 45.5% | -87.2% | – |
| Operating Cash Flow | $74,288 | $63,956 | $20,323 | $40,381 |
| Capital Expenditures | -$388 | $98,541 | -$98,838 | -$453 |
| Free Cash Flow | $73,900 | $162,497 | -$78,515 | $39,928 |